Further, data on cancer therapeutic responses to immune therapy indicated that cohorts with melanoma or bladder cancer and high TAP1 expression had a greater proportion of responders, indicating that patients with melanoma and bladder cancer and high TAP1 levels had both worse clinical prognosis and were potentially more sensitive to ICI therapy. The gene discussed is TAP1; the disease is urinary bladder carcinoma.